Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan ...
The Cato Corporation (NYSE: CATO) today reported a net loss of ($10.7) million or ($0.55) per diluted share for the fourth quarter ended January 31, 2026, compared to a net loss of ($14.1) million or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results